SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Amgen Inc. (AMGN)
An SI Board Since December 1996
Posts SubjectMarks Bans Symbol
1906 112 0 AMGN
Emcee:  trevor john wilkinson Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1831Effective treatment of bone mets has no effect on advanced PC survival. Talk abotom pope-12/25/2010
1830db: Study 147 hits primary but no benefit in survival - Leaves room for many quemopgcw-12/24/2010
1829sorry, dont have the GS report.mopgcw-12/20/2010
1828Thanks, missed that one; though it's a bit far out to put in our models rightuck-12/20/2010
1827Do we have GS (Goldman’s) report on AMGN? I wonder what she felt with most receXpiderman-12/20/2010
1826<i>>This [the prostate trial] is the only prevention trial Amgen is runDewDiligence_on_SI-12/19/2010
1825citi:Amgen Inc (AMGN) Alert: Who Says Miracles Don't Happen in Biotech-Xgevamopgcw-12/18/2010
1824CS: Near-Term Opportunity Offset by Long-Term Outlook: Biosimilars a Bigger Focumopgcw-12/18/2010
1823cs: Amgen Inc. (AMGN) NEUTRAL R. Mehrotra CP: US$ 54.04 TP: US$ 58 CAP: US$ 51.1mopgcw-12/18/2010
1822seekingalpha: Amgen's Prostate Cancer Drug Attracts Renewed Enthusiasm From mopgcw-12/17/2010
1821A fly in the ointment is that the one secondary endpoint that was missed is Overtuck-12/14/2010
1820Up 3%. Good excuse to get out of the legacy business I guess.keokalani'nui-12/14/2010
1819Yes! up $4 AH. hopefully will see a little more pop in the morning.mopgcw-12/13/2010
1818>>XGEVA (Denosumab) Significantly Improved Bone Metastasis-Free Survival ituck-12/13/2010
1817CS: Amgen Inc. (AMGN) NEUTRAL [V] Industry Weighting: OVERWEIGHT R. Mehrotra CPmopgcw-12/13/2010
1816zacks: Amgen (AMGN) reported third quarter earnings per share of $1.35, 9 cents mopgcw-10/30/2010
1815cc seekingaplha: Amgen Q3 2010 Earnings Call Transcript October 26, 2010 Execumopgcw-10/26/2010
1814AC meeting on ESAs today . . . THOUSAND OAKS, Calif., Oct. 18 /PRNewswire-Ftuck-10/18/2010
1813From DB 8/16/10: Amgen Next major catalyst: Outcome of Dmab Study 147 in Q4:10.mopgcw-8/17/2010
1812I tend to agree, that no one noticed this/cares...Amgen Oncology Drug Vectibix Dmopgcw-8/14/2010
1811reuters.com IMO--considering current mood of the FDA, they will have a huge mouArthur Radley-8/5/2010
1810>>Affymax and Takeda Announce Preliminary U.S. Registration Strategy for Ituck-8/5/2010
1809A fly in the ointment for Denosumab in cancer indications is that Zometa goes geDewDiligence_on_SI-6/6/2010
1808citi: From Provenge to Dmab and Beyond Prostate Cancer Doc Says Provenge Will bemopgcw-6/6/2010
1807With volatility so high these days, AH trades are tougher than they used to be imopgcw-6/2/2010
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News